Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825260 | 0.75 | — | — | |
| SCHEMBL301057 | 0.75 | — | — | |
| SCHEMBL4821291 | 0.75 | — | — | |
| SCHEMBL128482 | 0.75 | — | — | |
| SCHEMBL9069392 | 0.73 | PKM (0.39) | TSHRALDH1A1L3MBTL1THRB | |
| Hydrochloric Acid SCHEMBL16600366 | 0.73 | PKM (0.39) | TSHRALDH1A1L3MBTL1THRB | |
| SCHEMBL11571346 | 0.73 | TSHR (0.37) | TSHRALDH1A1THRB | |
| SCHEMBL1372401 | 0.73 | PKM (0.39) | TSHRALDH1A1L3MBTL1THRB | |
| Ammonia Solution, Strong SCHEMBL29007565 | 0.73 | PKM (0.39) | TSHRALDH1A1L3MBTL1THRB | |
| SCHEMBL28804484 | 0.73 | PKM (0.39) | TSHRALDH1A1L3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299325-A1 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | ENZENE BIOSCIENCES LIMITED (IN) | 2024-09-12 | — | — | US | claimed |
| EP-3810121-A1 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | Enzene Biosciences Ltd. (IN) | 2021-04-28 | — | — | EP | claimed |
| CN-112292123-A | Succinic acid and derivatives for the treatment of hematological disorders | 恩泽生物科学有限公司 | 2021-01-29 | — | — | CN | claimed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | claimed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | claimed |
| WO-2019244133-A1 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | ENZENE BIOSCIENCES LIMITED (IN) | 2019-12-26 | — | — | WO | claimed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | claimed |
| EP-1913007-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2011-06-22 | — | — | EP | claimed |
| US-20260116798-A1 | EFFECTIVE TREATMENT OF CHLOROTRIFLUOROETHYLENE (CTFE) OLIGOMERS AND DERIVATIVES | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240299325-A1 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | ENZENE BIOSCIENCES LIMITED (IN) | 2024-09-12 | — | — | US | disclosed |
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | SYNVENTA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-5235069-A | Process for the preparation of difluoromaleic anhydride and intermediate compounds produced thereby | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1992008710-A1 | PROCESS FOR THE PREPARATION OF DIFLUOROMALEIC ANHYDRIDE AND INTERMEDIATE COMPOUNDS PRODUCED THEREBY | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5112993-A | Process for the preparation of difluoromaleic anhydride | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0478195-A1 | Dihydropyridazinones, pyridazinones and related compounds as fungicides | ROHM AND HAAS COMPANY (US) | 1992-04-01 | — | — | EP | disclosed |
| US-4755579-A | Autoaccelerated organopolysiloxane elastomers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-07-05 | — | — | US | disclosed |
| US-4584256-A | AGING RESISTANCE | RHONE-POULENC SYSTEMES (FR) | 1986-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | TSHR 1153/4885ALDH1A1 235/4885L3MBTL1 4529/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | TSHR 1153/4885ALDH1A1 235/4885L3MBTL1 4529/4885 |
| US-20230381144-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | TRPV1, OPRL1, ADRA2C | TSHR 2245/4885ALDH1A1 1427/4885L3MBTL1 3896/4885 |
| US-20240299325-A1 | SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERS | STIP1, SORD, DLST | TSHR 4077/4885ALDH1A1 151/4885L3MBTL1 2817/4885 |
| US-20260116798-A1 | EFFECTIVE TREATMENT OF CHLOROTRIFLUOROETHYLENE (CTFE) OLIGOMERS AND DERIVATIVES | ALDOA, PFKFB2, MGAM | TSHR 1960/4885ALDH1A1 739/4885L3MBTL1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.